Volume 2.36 | Sep 23

Mammary Cell News 2.36 September 23, 2010.
In this issue: Science News  |  Current Publications  |  Industry News  |  Policy News  |  Events Subscribe  |  Unsubscribe

TOP STORY

Mayo-Led Researchers Discover Genetic Variants Modifying Breast Cancer Risk  ShareThis
Individuals with disrupting mutations in the BRCA1 gene are known to be at substantially increased risk of breast cancer throughout their lives. Now, researchers show that some of those persons may possess additional genetic variants that modify their risk. [Press release from Mayo Clinic discussing online prepublication in Nature Genetics]

Request a Free Sample  
New Defined Medium – EpiCult®-C
For Robust Growth of Human Mammary Luminal and Myoepithelial Cells
by STEMCELL Technologies
 
 
REQUEST A FREE SAMPLE STEMCELL Technologies Inc
 



SCIENCE NEWS

Krag Publishes Largest-Ever Breast Cancer Surgery Study
A less invasive surgical procedure for detecting breast cancer spread has for the first time been proven to achieve the same cancer survival and recurrence control as traditional lymph node removal surgery in patients whose initial sentinel node biopsy tested negative for cancer. [Press release from The University of Vermont discussing online prepublication in The Lancet Oncology]

Molecule 968 Binds Glutaminase and Starves Cancer Cells, say Cornell Biologists
A molecule – simply called 968 – can starve cancer cells and the tumors they produce, says new research. [Press release from Cornell University discussing online prepublication in Cancer Cell]

Fat Stem Cells Safe for Breast Reconstruction when Cancer is Dormant, Says Pitt Team
Fat-derived stem cells can be safely used to aid reconstruction of breast tissue after mastectomy as long as there is no evidence of active cancer, according to researchers. [Press release from the University of Pittsburgh discussing online prepublication in Tissue Engineering Part A]

Stress Before Cancer Therapy Could Help Deadly Cells Survive Treatment, Lead to Disease Recurrence
Patients who experience physical or psychological stress – including rigorous exercise – one or two days before a cancer treatment might be unknowingly sabotaging their therapy, new research suggests. [Press release from the Ohio State University discussing online prepublication in Molecular Cancer Research]

ALDEFLUORCSC_645x110



CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

LABORATORY RESEARCH

Targeting Mitochondrial Glutaminase Activity Inhibits Oncogenic Transformation
Researchers describe a small molecule inhibitor that blocks oncogenic transformation induced by various Rho GTPases in fibroblasts, and the growth of human breast cancer and B lymphoma cells, without affecting normal cells. [Cancer Cell]

CSPG4 Protein as a New Target for the Antibody-Based Immunotherapy of Triple-Negative Breast Cancer
This study identified chondroitin sulfate proteoglycan 4 (CSPG4) as a new target for triple-negative breast cancer (TNBC). The antitumor activity of CSPG4-specific monoclonal antibody was mediated by multiple mechanisms, including the inhibition of signaling pathways crucial for TNBC cell survival, proliferation, and metastasis. [J Natl Cancer Inst]

The Wnt Antagonist Dickkopf-1 Increases Endothelial Progenitor Cell Angiogenic Potential
By studying 62 human breast tumors, researchers found a significant positive correlation between Wnt antagonist Dickkopf-1 (DKK1) expression and von Willebrand factor. In vivo, DKK1 strongly enhanced the vascularization of Matrigel plugs and increased tumor size in a xenograft model of human breast carcinoma in nude mice. [Arterioscler Thromb Vasc Biol]

IGFBP-3 can Either Inhibit or Enhance EGF-Mediated Growth of Breast Epithelial Cells Dependent Upon the Presence of Fibronectin
Researchers have examined the effects of an insulin-like growth factor binding protein (IGFBP-3) on EGF-responses of breast epithelial cells in the context of changes in the extracellular matrix. [J Biol Chem]

Hsp27 Protects Adenocarcinoma Cells from UV-Induced Apoptosis by Akt and p21-Dependent Pathways of Survival
The results showed that Hsp27 expression and its direct chaperoning interaction increases Akt stability, and p21 phosphorylation and nuclear-to-cytoplasm translocation, both essential effects for the survival of UV-induced DNA-damaged cells. [Mol Cancer Res]

Results of the CONFIRM Phase III Trial Comparing Fulvestrant 250 mg With Fulvestrant 500 mg in Postmenopausal Women With Estrogen Receptor-Positive Advanced Breast Cancer
Researchers compared fulvestrant 500 mg regimen with the approved dose of fulvestrant 250 mg per month for treatment of postmenopausal women with estrogen receptor-positive advanced breast cancer who experienced progression after prior endocrine therapy. [J Clin Oncol]

Sentinel-Lymph-Node Resection Compared with Conventional Axillary-Lymph-Node Dissection in Clinically Node-Negative Patients with Breast Cancer: Overall Survival Findings from the NSABP B-32 Randomised Phase III Trial
The aims of National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-32 were to establish whether sentinel-lymph-node resection in patients with breast cancer achieves the same survival and regional control as axillary-lymph-node dissection, but with fewer side-effects. [Lancet Oncol]



INDUSTRY NEWS

Celldex Therapeutics Announces Initiation of Randomized Phase IIb Clinical Trial of CDX-011 in Advanced Breast Cancer
Celldex Therapeutics, Inc. announced that the first patient has been treated in a randomized Phase IIb study of the Company’s CDX-011 (glembatumumab vedotin) antibody drug conjugate in glycoprotein NMB (GPNMB) expressing advanced, refractory breast cancer patients. [Celldex Therapeutics, Inc. Press Release]

Celsion Announces ThermoDox(R) Abstract Accepted at the 2010 Breast Cancer Symposium
Celsion Corporation announced that an abstract on its Phase I/II DIGNITY trial of ThermoDox(R) in Recurrent Chest Wall (RCW) Breast Cancer has been accepted for a poster session at the 2010 Breast Cancer Symposium. [Celsion Corporation Press Release]

Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer
Boehringer Ingelheim announced the initiation of a phase III clinical trial to investigate one of its most advanced oncology pipeline compounds, afatinib, for the treatment of patients with advanced (metastatic) breast cancer. [Boehringer Ingelheim Press Release]

Genentech Provides Update on Avastin for Advanced Breast Cancer
Genentech, Inc., announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin® (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment. [Genentech, Inc. Press Release]



POLICY NEWS

NHGRI Funds Development of Third Generation DNA Sequencing Technologies
More than $18 million in grants to spur the development of a third generation of DNA sequencing technologies was announced by the National Human Genome Research Institute. [National Institutes of Health, United States]

Innovative Emerging Molecular Analysis Technologies (SBIR R43/R44) (RFA-CA-10-013) [National Institutes of Health, United States]

Prospective Grant of Exclusive License: The Development of Immunotoxins/Targeted Toxins for the Treatment of Human Cancer (FR Doc. 2010-22844) [National Institutes of Health, United States]

National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-23027) [National Institutes of Health, United States]

National Cancer Institute; Notice of Closed Meeting (FR Doc. 2010-23144) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23143) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meetings (FR Doc. 2010-23275) [National Institutes of Health, United States]

Agenda for the Public Workshop on Cell and Gene Therapy Clinical Trials in Pediatric Populations [Food and Drug Administration, United States]



EVENTS (Listed by Date)

Cellular Therapy of Cancer Symposium – ATTACK Project Meeting
September 24-27, 2010
Montpellier, France

International Society for Cellular Therapy 2nd Annual Symposium on Stem Cell Translation: Best Practices & Regulatory Considerations
September 27-28, 2010
San Francisco, United States

NEW  4th American Association of Cancer Research International Conference on Molecular Diagnostics in Cancer Therapeutic Development: Challenges and New Horizons
September 27-30, 2010
Denver, United States

Expert Perspectives: Integrating New Data into Best Practices for Breast Cancer
October 1, 2010
National Harbor, United States

2010 Breast Cancer Symposium
October 1-3, 2010
Washington, DC, United States

NEW 2010 World Stem Cell Summit
October 4-6, 2010
Detroit, United States

2nd International Inflammatory Breast Cancer Conference
October 6-7, 2010
Marseille, France

35th European Society for Medical Oncology (ESMO) Congress
October 8-12, 2010
Milan, Italy

NEW  Institute for Genomic Medicine Inaugural Symposium
October 11-12, 2010
San Diego, United States

New York Stem Cell Foundation 5th Annual Translational Stem Cell Research Conference
October 12-13, 2010
New York City, United States

International Symposium on Breast Cancer Prevention: Nutrition, Communications, Public Policy
October 18-19, 2010
West Lafayette, United States

16th World Congress of the International Society of Senology
October 20-22, 2010
Valencia, Spain

NEW  6th Modern Drug Discovery & Development Summit (M3D)
October 20-22, 2010
San Francisco, United States

The 2010 American Institute for Cancer Research (AICR) Annual Research Conference on Food, Nutrition, Physical Activity & Cancer
October 21-22, 2010
Washington, DC, United States

MENA Oncology Conference
October 22-23, 2010
Cairo, Egypt

NEW Frontiers in Tumour Progression
October 24-27, 2010
Madrid, Spain

NEW  World Stem Cells & Regenerative Medicine Congress Asia 2010
October 26-28, 2010
Seoul, Korea

UAE Cancer Congress 2010
October 28-30, 2010
Dubai, United Arab Emirates

NEW FDA Public Workshop on Cell and Gene Therapy Clinical Trials in Pediatric Populations
November 2, 2010
North Bethesda, United States

NEW 9th Annual AACR International Conference: Frontiers in Cancer Prevention Research
November 7-10, 2010
Philadelphia, United States

6th National Cancer Research Institute (NCRI) Conference
November 7-10, 2010
Liverpool, United Kingdom

NEW The 16th International Conference of the International Society of Differentiation: From Stem Cells to Organisms
November 15-18, 2010
Nara, Japan

22nd EORTC-NCI-AACR Symposium on “Molecular Targets and Cancer Therapeutics”
November 16-19, 2010
Berlin, Germany

Clinical Dilemmas in Management of Breast and Ovarian Cancer in BRCA Carriers
November 18-19, 2010
Tel Aviv, Israel

33rd Annual San Antonio Breast Cancer Symposium
December 8-12, 2010
San Antonio, United States

NEW Epithelial Plasticity and Epithelial to Mesenchymal Transition
January 21-26, 2011
Vancouver, Canada

NEW  Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

NEW American Association for Cancer Research (AACR) Stem Cells, Development, and Cancer
March 3-6, 2011
Vancouver, Canada

28th Annual Miami Breast Cancer Conference
March 9-12, 2011
Miami, United States

NEW American Association for Cancer Research (AACR) 102nd Annual Meeting 2011
April 2-6, 2011
Orlando, United States

NEW  International Society for Stem Cell Research (ISSCR) 9th Annual Meeting
June 15-18, 2011
Toronto, Canada

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.


JOB OPPORTUNITIES

Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cell Therapy News.
Visit here to post your career opportunities.


Have we missed an important article or publication in Mammary Cell News? Click here to submit!


Learn more about Mammary Cell News: Archives  |  Events  |  Subscribe  |  Contact Us